Klin Farmakol Farm. 2003;17(3):166-169

Moderní nesteroidní antirevmatika: klady a zápory

David Suchý1, Marek Reichl2
1 Oddělení klinické farmakologie, FN Plzeň
2 Klinika ortopedie a traumatologie, Fakultní nemocnice, Plzeň

Selektivní inhibitory cyklooxygenázy byly vyvinuty jako odpověď na gastrointestinální toxicitu konvenčních NSA. Základní a klinická data konstatují menší počet gastrointestinálních nežádoucích účinků, ale potencionální protrombogenní efekt těchto léků vyžaduje jejich další sledování, zejména u pacientů s kardiovaskulárními onemocněními s vysokým rizikem KV příhod.

Keywords: COX-2 inhibitors, gastrointestinal tolerance, prostaglandins, prothrombotic effect.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Suchý D, Reichl M. Moderní nesteroidní antirevmatika: klady a zápory. Klin Farmakol Farm. 2003;17(3):166-169.

Selektivní inhibitory cyklooxygenázy byly vyvinuty jako odpověď na gastrointestinální toxicitu konvenčních NSA. Základní a klinická data konstatují menší počet gastrointestinálních nežádoucích účinků, ale potencioální protrombogenní efekt těchto léků vyžaduje jejich další sledování zejména u pacientů s kardiovaskulárními onemocněními s vysokým rizikem KV příhod.

Contemporary nonsteroidal antiinflamatory drugs: advantages and disadvantages

Selective cyklooxygenaze inhibitors were developed as a response to the gastrointestinal toxicity of conventional NSAIDs. Basic and clinical data suggest, that they have less gastrointestinal adverse events, but the potentially prothrombotic effect of this class of drugs mandates theier other evaluation mainly in patients with cardiovascular diseases, who are at risc for cardiovascular events.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Peterson WL, Cryer B. COX-1-sparing NSAIDs - is the enthusiasm justified? JAMA 1999; 282: 1961-1963. Go to original source... Go to PubMed...
    2. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769-772. Go to original source... Go to PubMed...
    3. Singh G, Triadafilopoulos G. Epidemiology of NSAID-induced gastrointestinal complications. J Rheumatol 1999; 26: Suppl 26: (18-24). Go to PubMed...
    4. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 787-796. Go to original source... Go to PubMed...
    5. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119:257-262. Go to original source... Go to PubMed...
    6. Lipsky, et al.The classification of cyclooxygenase inhibitors. J Rheumatol 1998; 25: 2298-2303. Go to PubMed...
    7. Pavelka K. Selektivní inhibitory cyklooxygenázy II - nová kvalita ve vývoji nesteroidních antirevmatik. Remedia 1997; 7: 362-369.
    8. Vane JR. Mechanism of action of NSAIDs. BrJ Rheumatol 1996; 35: 1-3. Go to original source... Go to PubMed...
    9. Bennet A, Berti F, Ferreira SH. Nimesulid: a multifactorial therapeutic approach to the antiinflamatory proces? A 7-year clinical experience:Drugs 1993: 46: (Sppl.1) 1-283.
    10. Wenke M. Nimesulidum Remedia 1998; 8: 137-147.
    11. Boelsterli UA. Mechanism of NSAID-induced hepatotoxicity: Focuse on nimesulide. Drug Safety 2002; 25 (9): 633-648. Go to original source... Go to PubMed...
    12. Garcia Rodriguez LA, Cattaruzzi C. Troncon MG, et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs Int Med 1998: 3-39. Go to original source...
    13. Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998; 37: 937-945. Go to original source... Go to PubMed...
    14. Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37: 946-951. Go to original source... Go to PubMed...
    15. Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med 1999; 107: 48-54. Go to original source... Go to PubMed...
    16. Horák P. Současný pohled na účinnou a bezpečnou léčbu nesteroidními antirevmatiky. Interní medicína pro praxi 2002; 7: 336-340.
    17. Štolfa J. Meloxicamum. Remedia 1998; 8:194-204.
    18. Degner F. Lanes S, van Ryn J, Sigmund R. Pharmacological and clinical profile of meloxicam In: Therapeutic roloe of selective COPX-2 inhibitors. Edited by Vane JR, Motting RM. Wiliam Harvey Press London 1991.
    19. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial: Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255. Go to original source... Go to PubMed...
    20. Statistical reviewer briefing document for the Advisory Committee. Rockville, Md. Food and Drug Administration, 2000. (Accessed November 4, 2002, at www. fda.gov/ohrms/dosckets /ac/01.
    21. Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000; 38: 225-242. Go to original source... Go to PubMed...
    22. Depre M, Ehrich E, Van Hecken A, et al. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000; 56: 167-174. Go to original source... Go to PubMed...
    23. Chan FKL, Chung SCS, Bing YS et al.Celecoxib versus Diclofenac and Omeprazole in reducting the Risc of Recurrent Ulcer Bleeding in Patients with Arthritis. N Engl J Med. 2002; 347: 2164-2110. Go to original source... Go to PubMed...
    24. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-1528. Go to original source... Go to PubMed...
    25. Langman MJ, Jensen DM, Watson DJ, et al. Adverse Upper Gastrointestinal Effects Of Rofecoxib Compared with NDAIDs.JAMA 1999; 282: 1929-1933. Go to original source... Go to PubMed...
    26. Konstant MA, Weir MR, Reicin A,et al. Cardiovascular Thrombotic Events in Controlled Trials of Rofecoxib.Circulation 2001; 104: 2280. Go to original source... Go to PubMed...
    27. Watson DJ, Rhodes T,Cai B, et al. Lower Risc of Tromboembolic Events With Naproxen Among Patients With Rheumatoid Arthritis. Ann. Intern Med 2002; 162:1105-1110. Go to original source... Go to PubMed...
    28. Solomon DH, Glynn JR, Levin R, et al. Nonsteroidal antiinflamatory Drug Use an Acute Myocardial Infarction. Arch Intern Med 2002; 162: 1099-1104. Go to original source... Go to PubMed...
    29. Garcia Rodriguez LA, Varas C, Patrono C. Differential effect of aspirin and non - aspirin nonsteroidal antiinflamatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11(4): 371-374. Go to original source... Go to PubMed...
    30. Kozák J,Vrba I. Koxiby v pooperační péči. Bolest 2002; 3: 156-159.
    31. Pavelka K, Štolfa J. Uplatnění Koxibů v léčbě bolesti u osteoartrózy a revmatoidní artritidy. Bolest 2002: 2: 89-96.
    32. Riendeau D, Percival MD, Brideau C, et al.Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296: 558-566. Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.